Summary of COVID-19 posaconazole studies

1. Prattes et al., Posaconazole for Prevention of COVID‐19‐Associated Pulmonary Aspergillosis in Mechanically Ventilated Patients: A European Multicentre Case–Control Study (POSACOVID)

249 patient posaconazole prophylaxis study: 131% higher mortality (p<0.0001) and 54% improvement (p=0.41).
Prospective matched case-control study of 249 mechanically ventilated COVID-19 patients in Europe, showing variable impact of posaconazole prophylaxis on COVID-19-associated pulmonary aspergillosis (CAPA) incidence depending on baseline CAPA rates. Authors note: "Most of the currently available evidence on antifungal prophylaxis in critically ill COVID-19 patients is showing a reduction of CAPA rates (generally prevalence rates are given) but no significant difference in overall survival rates." Mortality results for this study are from the registry and are not reported in the paper.
Jan 2025, Mycoses, https://onlinelibrary.wiley.com/doi/10.1111/myc.70023, https://c19p.org/prattes